Campath - Newsfeeds

Sanofi, Genzyme Agree On Due Diligence Amidst Merger Talks - Update: However, the CVR structure has been a contentious issue between the two companies. At stake, is valuation of Genzyme's multiple sclerosis drug Campath, known generically as alemtuzumab and to be branded as Lemtrada. While, Genzyme predicts revenues of ...
Sanofi Aventis Raises Bid For Genzyme Brining Deal Closer: According to a report in the New York Times , the experimental drug is Campath, a drug that is used to fight leukemia but that is also being tested for use against multiple sclerosis under the Lemtrada name. The acquisition talks came about after some of ...
Pancreas Allograft Biopsies with Positive C4d Staining and Anti-donor Antibodies Related to ...: Alm = alemtuzumab; ATG = anti-thymocyte globulin; Bas = basilixumab; biopsy (days), number of days after transplantation that biopsy was taken; CIT = cold ischemia time; creat = creatinin; Dac = daclizumab;
Genzyme rejects Sanofi offer: the tremendous future upside of our multiple sclerosis drug alemtuzumab, and our outlook for significant cost reductions that will further drive our earnings growth. Moreover, last week’s public announcement that ...
Genzyme confirms receipt of unsolicited proposal: the tremendous future upside of our multiple sclerosis drug alemtuzumab, and our outlook for significant cost reductions that will further drive our earnings growth. Moreover, last week’s public announcement that ...
Genzyme rejects Sanofi-Aventis 'bear hug': Genzyme is appealing because of its multiple sclerosis drug Campath, which could reach the market in 2012, plus a cholesterol lowering treatment, mipomersen, which is in late-stage clinical trials. Anderson said that ...
Genzyme rejects $21bn Sanofi offer: the future of experimental multiple-sclerosis treatment Campath, and expectations of future cost cuts that will drive earnings growth. The French drug giant warned that Genzyme still has a long way to go before ...
FTSE 100 above 5500 ahead of Basel meeting, as Rightmove rises on bid talk: and was not expecting a large Campath deal between Genzyme and Bayer. BTG has taken the correct strategy to develop drugs in out-licensing and stands to benefit from leveraging a solid revenue-generating intellectual ...
Investors: Genzyme sale is inevitable: Only 44% of respondents in the survey believe Campath, Genzyme's experimental multiple sclerosis drug, will be a technical or commercial success. And Genzyme is likely to lose about 40% of patients for its two key ...
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer: which includes alemtuzumab (Campath) for multiple sclerosis that the company feels is a potential big seller. Today's release is Genzyme's first public acknowledgement of the buyout talks between it and Sanofi ...

Genzyme Snubs Sanofi-Aventis' Acquisition Offer: with a turnaround projected through its promising multiple-sclerosis drug Campath. The deal could see Sanofi-Aventis bolster its drug pipeline and significantly increase its presence in the biopharmaceutical sector.
Farmacêutica americana acha que vale mais: o Campath, atualmente em processo de aprovação pela autoridade americana de fiscalização de remédios e alimentos, conhecida como FDA. O Campath atualmente é liberado para tratar leucemia. Viehbacher disse que a ...
Billion-dollar drugs: The drug is a new version of a monoclonal antibody it already markets for leukemia under the name Campath. There are five drugs approved to treat relapsing remitting multiple sclerosis, including two marketed by ...
Genzyme Touts Value Of MS Drug, But View May Be Optimistic: Genzyme Chief Executive Henri Termeer stressed the "tremendous future upside of our multiple sclerosis drug alemtuzumab," which is the generic name for the MS drug Campath, as among the reasons for Sanofi's offer ...
Genzyme's Honey Won't Be Sweet Enough for Sanofi: The cancer and potential MS drug Campath. The drug is currently approved for the treatment of leukemia and is in late-stage testing for multiple sclerosis. It just so happens that there are potential synergies ...
Genmab Announces Change in Management: a new treatment for patients with fludarabine and alemtuzumab refractory CLL. The Chief Executive Officer position at Genmab will be filled by Prof. Jan G.J. van de Winkel, Ph.D., the company's former President, Research ...
Genzyme MS drug gets FDA fast track: The U.S. Food and Drug Administration has granted fast track status to Genzyme Corp.'s multiple sclerosis drug target, alemtuzumab. The fast track designation makes the drug candidate eligible for priority review by the ...
FDA grants fast-track status to Genzyme MS drug: Genzyme has said the drug, called alemtuzumab, is one of its most important experimental products. It is being tested for the relapsing-remitting form of multiple sclerosis -- the most common type of the progressive ...
Genzyme MS drug granted fast track status: Genzyme Corp ., a large Cambridge biotechnology company, said that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the US Food and Drug Administration. This designation ...
Genzyme not for sale; drug on ‘fast track’: Genzyme also announced yesterday that its multiple sclerosis drug candidate, alemtuzumab, was granted a speedy review by the Food and Drug Administration. The FDA grants “fast track” status to drug candidates that ...

Want to contact a District of Columbia Campath attorney? ...Get a free case evaluation from one of our District of Columbia Campath attorneys now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 3 Next

Need A Campath Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Campath Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Campath Information

Click to View Our Legal Resources

Want to contact a District of Columbia Campath attorney? ...Get a free case evaluation from one of our District of Columbia Campath attorneys now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120223-010823

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Campath Click to select a Legal Issue

Close (x)

Find Legal Help for Your Campath Case - Submit Your Information Below

Do you need legal assistance with your Campath case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Campath Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.